Notice of Investor Presentation

Summary by AI ^BETAClose X

SkinBioTherapeutics plc has announced a presentation for shareholders scheduled for 9am BST on Monday, June 29, 2026, which will be led by the Acting Chair and Interim CEO. This presentation is accessible to all current and prospective shareholders, with the opportunity to submit questions in advance via the Investor Meet Company dashboard until 9am BST on June 28, 2026, or during the live event. Investors can register for free on the Investor Meet Company platform to receive an invitation.

Disclaimer*

SkinBioTherapeutics PLC

23 June 2026

A blue text on a white background Description automatically generated

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company" or the "Group")

Notice of IMC presentation

23 June 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life sciences business focused on skin health, will be presenting to shareholders at 9am BST on Monday 29 June 2026. The presentation will be led by Alyson Levett, Acting Chair and Rachel Parsonage, Interim CEO.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 28 Jun 2026, 9am BST, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet SkinBioTherapeutics via the link HERE. Investors who already follow SkinBioTherapeutics on the Investor Meet Company platform will automatically be invited.

-Ends-

For more information please contact:

SkinBioTherapeutics plc Alyson Levett, Acting Chair Rachel Parsonage, Interim CEO	ir@skinbiotix.com
Singer Capital Markets (Nominated Adviser & Broker) Alex Bond Sara Hale Patrick Weaver	+44 (0) 020 7496 3000
Vigo Consulting Melanie Toyne-Sewell, Rozi Morris	+44 (0) 20 7390 0230 SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life sciences company focused on skin health. The Group's proprietary platform technology, SkinBiotix^®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Company's strategic approach to skin health is via two routes - tackling skin issues from the 'outside in' and the 'inside out'. The 'outside in' approach is represented by topical creams, and from the 'inside out', via oral supplement solutions which impact the skin via different axes such as the gut and the brain.

SkinBio's products and services are developed through evidence-based science and commercially focused innovation with the aim of supporting skin health, well-being, repair and beauty. SkinBio also has a contract manufacturing and distribution arm related to skin health and other healthcare products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.SkinBioTherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END